Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2020 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia ...
December 30, 2019 06:15 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response

Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p<0.001) and freedom from most bothersome symptom (p=0.002) at 2 hours, compared to placebo Demonstrated...
December 23, 2019 16:19 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the...
December 19, 2019 07:05 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (Nasdaq: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the...
December 18, 2019 16:01 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (Nasdaq: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the...
December 17, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Added to NASDAQ Biotechnology Index

NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
December 16, 2019 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder

Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint) Statistically...
December 03, 2019 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS;...
November 21, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine

Company to host conference call on Monday, November 25 at 9:00 AM Eastern NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
November 07, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient...